MedTrace Logo

Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus

NCT00865592 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2010-08-11

No results posted yet for this study

Summary

The purpose of this study is to demonstrate that dutogliptin/PHX1149T is safe and tolerable.

Conditions

Interventions

DRUG

dutogliptin

dutogliptin 400 mg, once daily tablet

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • Phenomix

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2011-01-31
Completion
2011-03-31

Countries

  • United States
  • Argentina
  • India
  • Malaysia
  • Peru
  • Philippines
  • Romania
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00865592 on ClinicalTrials.gov